Pfizer’s COVID-19 vaccine receives a go-ahead sign from FDA Expert Panel

2 min read | December 11, 2020 04:40 PM AEDT | By Team Kalkine Media

Summary

  • An FDA expert panel in the US gave their nod for Pfizer's vaccine for emergency use.
  • FDA's formal approval for Pfizer-BioNTech coronavirus vaccine is expected shortly.
  • Pfizer has said that the recommendation is based on scientific evidence.

In a significant recent development, the Pfizer-BioNTech coronavirus vaccine gets FDA officials panel's nod for the Emergency Use Authorization (EUA) of the vaccine. The Vaccines and Related Biological Products Advisory Committee (VRBPAC) has endorsed the use of Pfizer coronavirus vaccine in the US. 

Image source: Shutterstock

The Board had a meeting to decide whether the Pfizer-BioNTech coronavirus vaccine outweigh the risks. The panel concluded with 17-4 vote with one abstention that the vaccine looks safe and efficient against the COVID-19 infection in the age group of 16 and above.

The vaccine has already been granted for the public use in the UK, Bahrain, Canada, and Saudi Arabia. In the US it still needs an official FDA approval which is expected soon. The Pfizer vaccine has been one of the front liners in coronavirus vaccine race in the US. There were speculations of it getting approved before the presidential elections in November.

Related: Pfizer to Roll Out COVID-19 Vaccine Just Before the US Election

There is an urgent requirement for an effective vaccine in the country as the superpower US has been one of the most adversely impacted nations due to the ongoing COVID-19 pandemic. As per WHO, between 3 January 2020 to 10 December 2020 (5:46 PM CET), the total confirmed cases in the US were 14,972,356 with 283,994 deaths. 

Pfizer is pleased with the recommendation

Source: Pfizer’s website

Pfizer has reported that the experts' group had based their vaccine endorsement on the scientific evidence shared in the clinical trials report. The phase 3 data showed the vaccination efficacy of around 95% in people with no prior COVID-19 infection.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.